415 Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study

• DOI: 10.1136/jitc-2020-sitc2020.0415
• Publication Date: 2020-11-09T19:11:59Z
• Authors: Kunkun Li; Xiao Yang; Wei Luo; Qiang Ma; Yingjian Wang; Yanli Xiong; Xiaolong Zhao; Xianfeng Lu; Tao Bao; Wei Guo; Mengxia Li
• Keywords: Carboplatin; Regimen; Neoadjuvant Therapy; Single Center; Esophagectomy

<h3>Background</h3> Several immune checkpoint inhibitors (ICIs), represented by programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) antibodies, have been approved for treatment of various malignant tumors (including advanced esophageal cancer) worldwide, and previous studies confirmed that they can significantly improve overall survival.¹ However, there has limited research on the use ICIs as neoadjuvant therapy patients with cancer. Toripalimab is a humanized IgG4 monoclonal antibody targets PD-1. The objective this study to evaluate efficacy safety toripalimab plus chemotherapy regimen locally squamous carcinoma (ESCC). <h3>Methods</h3> This single-arm, single-center enrolled ESCC at clinical stage T2-T4/N0-N2/M0, who were eligible radical resection regional lymph node dissection. received 2–3 cycles (240 mg d1, Q3W) in combination nab-paclitaxel (260 mg/m² carboplatin (AUC=5 before surgery. Preoperative evaluation was performed within 4 weeks after last administration chemotherapy. primary endpoints pathologic complete response (PCR) major (MPR), secondary feasibility immunotherapy. <h3>Results</h3> Seventeen diagnosed pre-treatment T2-T4/N0-N2/M0 included. After therapy, 15 17 (88.2%) experienced downstaging met surgical criteria. Twelve (80.0%) underwent surgery without delay 3 (20.0%) refused completely removed all 12 (R0 rate: 100%). Seven (58.3%) achieved MPR 2 (16.7%) PCR. median post-surgical follow-up time 4.5 months, no recurrences. Treatment-related adverse events (TRAEs) tolerable. Grade or higher TRAEs occurred (11.8%), but these did not <h3>Conclusions</h3> showed promising anti-tumor activity acceptable tolerance ESCC, demonstrated reducing tumor burden, improving R0 rate, postoperative recurrence delays <h3>Acknowledgements</h3> N/A <h3>Ethics Approval</h3> Ethics Board Army Medical center PLA, approval number 142(2018). <h3>Consent</h3> Written informed consent obtained from patient publication abstract any accompanying images. A copy written available review Editor journal. <h3>Reference</h3> Wu X, Gu Z, Chen Y, et al. Application PD-1 blockade cancer <i>Comput Struct Biotechnol J</i> 2019;<b>17</b>:661–674.